The National Bleeding Disorders Foundation (NBDF) and Hemophilia Federation of America (HFA) are deeply concerned by the World Health Organization’s (WHO) recommendation of cryoprecipitate (pathogen-reduced and non-pathogen-reduced) in the 23rd Essential Medicines List (EML) for treatment for Hemophilia.
With FVIII concentrates available globally, the inclusion of cryoprecipitate as treatment for Hemophilia is an egregious, misguided recommendation that does not account for the inadequate safety of cryoprecipitate relating to the transmission of bloodborne illnesses, such as HIV and HCV. We call on the World Health Organization to include FVIII concentrates on the EML, outside of the complementary list.
This is the first step in what we expect to be continuing communications between our groups and the World Health Organization, ensuring that global treatment for bleeding disorders is both safe and effective.
This is an ongoing discussion and NBDF and HFA will keep the bleeding disorders community informed as information is gathered.
Please note that NBDF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.
